Press release
Key Influencer in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2025: Rising Incidence Of Multiple Myeloma Driver
B Cell Maturation Antigen BCMA Targeted TherapiesMarket Size
The b-cell maturation antigen (BCMA) targeted therapies market is forecasted to surge, driven by the escalating prevalence of multiple myeloma. This type of cancer predominantly occupies plasma cells, components of the immune system responsible for antibody production. This increasing prevalence is linked to factors including an elderly global population, advancements in diagnostic capabilities, and disparities in access to healthcare. Especially crucial in battling multiple myeloma, BCMA targeted therapies focus on the eradication of malignant plasma cells expressing BCMA, presenting a prospective approach for more efficient, pinpointed treatment. For instance, the American Cancer Society, a professional organization based in the US, reported that around 35,780 new multiple myeloma cases (comprising 19,520 male cases and 16,260 female cases) were identified in the US in August 2024. Furthermore, approximately 12,540 deaths are expected, of which 7,020 will be men and 5,520 women. Therefore, this growing prevalence is fueling the growth of the b-cell maturation antigen (BCMA) targeted therapies market.
Get Your B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report Here:
https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report
What is the projected compound annual growth rate (CAGR) of the b-cell maturation antigen (bcma) targeted therapies market from 2025 to 2034, and what factors influence it?
The market size of therapies targeting the B-cell maturation antigen (BCMA) has seen a significant increase in the past few years. The market is projected to rise from $12.17 billion in 2024 to $15.21 billion in 2025 with a compound annual growth rate (CAGR) of 25.0%. This surge during the historical period can be tied to the escalating emphasis on hematologic malignancies, increased investments in cancer research, surging requirement for personalized medicine, the expanding use of CAR-T cell therapies, and the overall increase in healthcare expenditure.
The market for B-cell maturation antigen (BCMA) targeted treatments is forecast to undergo substantial expansion in the coming years, with predictions showing that it will reach a value of $36.66 billion in 2029, reflecting a compound annual growth rate (CAGR) of 24.6%. This predicted growth during the forecast period is linked to several factors including an intensified concentration on cancer research, a shift towards targeted molecular markers, escalating cancer rates, an upswing in biotech investment and a rising utilization of cell and gene therapies. Forecast period trends that are anticipated to have a major impact include innovations such as CRISPR technology, progress in gene-editing technologies and the next wave of car-t cell therapies, improvements in targeted antibody-drug conjugates, and the production of off-the-shelf treatments.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
How are the latest trends influencing the growth of the b-cell maturation antigen (bcma) targeted therapies market?
Prominent players in the B-cell maturation antigen (BCMA) targeted therapies market are directing their efforts towards creating novel treatments like CAR-T cell therapy to improve the accuracy and effectiveness of targeting cancer cells. CAR-T cell therapy is a form of immunotherapy that modifies a patient's T cells to carry chimeric antigen receptors (CARs), enabling them to target and eradicate cancer cells. For instance, in April 2024, U.S. pharmaceutical giant Johnson & Johnson gained the approval of the U.S. Food and Drug Administration (FDA) for their product, CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy, intended to treat adult patients suffering from relapsed or refractory multiple myeloma who have undergone at least one previous line of therapy, and who are lenalidomide-resistant.
What are the major segments of the b-cell maturation antigen (bcma) targeted therapies market and their role in driving growth?
The B-cell maturation antigen (BCMA) targeted therapies market covered in this report is segmented -
1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia, Multiple Myeloma
3) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20718
Which regions are key players in the growth of the b-cell maturation antigen (bcma) targeted therapies market?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the key firms paving the way for growth in the b-cell maturation antigen (bcma) targeted therapies market?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20718&type=smp
What Is Covered In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report?
•Market Size Forecast: Examine the b-cell maturation antigen (bcma) targeted therapies market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the b-cell maturation antigen (bcma) targeted therapies market for a structured understanding.
•Key Players Overview: Analyze major players in the b-cell maturation antigen (bcma) targeted therapies market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the b-cell maturation antigen (bcma) targeted therapies market.
•Segment Contributions: Evaluate how different segments drive overall growth in the b-cell maturation antigen (bcma) targeted therapies market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the b-cell maturation antigen (bcma) targeted therapies market.
•Industry Challenges: Identify potential risks and obstacles affecting the b-cell maturation antigen (bcma) targeted therapies market.
•Competitive Landscape: Review strategic developments in the b-cell maturation antigen (bcma) targeted therapies market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Influencer in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2025: Rising Incidence Of Multiple Myeloma Driver here
News-ID: 3944640 • Views: …
More Releases from The Business Research Company
Consistent Growth Projected for Social-To-Earn Network Market, Reaching $7.34 Bi …
What Is the Projected Size of the Social-To-Earn Network Market by 2025?
The social-to-earn network sector has witnessed substantial, rapid expansion lately, with projections showing a rise from a valuation of $2.30 billion in 2024 to $2.91 billion the following year, reflecting a consistent compound annual growth rate (CAGR) of 26.4% across the forecast timeframe. This historical upward trajectory is fundamentally driven by several interconnected factors: enhanced global access to mobile…
Accelerated Digital Transformation Fuels Expansion in the Smart Ferry Electrific …
How Much Is the Smart Ferry Electrification Market Expected to Expand by 2025?
The sphere of smart ferry electrification has witnessed swift expansion lately, projected to advance from a valuation of $1.24 billion in 2024 to $1.42 billion in 2025, demonstrating a compound annual growth rate (CAGR) calculated at 14.9%. This expansion across the historical timeframe is linked to several key factors, including the increasing availability of governmental support and financial…
2025-2034 Single Port DC Wallbox Charger Market Evolution: Emerging Opportunitie …
What Is the Projected Size of the Single Port DC Wallbox Charger Market by 2025?
The market scope for single-port DC wallbox chargers has seen substantial recent expansion; specifically, its valuation is projected to increase from $1.03 billion in 2024 to reach $1.22 billion by 2025, reflecting a compound annual growth rate of 17.9%. This historical upswing is primarily driven by surging electric vehicle sales across the globe, the increasing deployment…
Shelf Image Recognition Artificial Intelligence Market Poised for Robust Growth, …
How Much Is the Shelf Image Recognition Artificial Intelligence Market Expected to Expand by 2025?
The artificial intelligence market focused on recognizing items on shelves has experienced a remarkable surge lately; this segment is projected to expand from generating $1.43 billion in 2024 to reaching $1.82 billion in 2025, reflecting an impressive compound annual growth rate of 26.8%. This substantial expansion observed during the past period stems from several key factors,…
More Releases for BCMA
BCMA-Targeted CAR-T Cell Therapy Market Poised for Robust Growth by 2033
London, UK - September 2025 | Strategic Revenue Insights Inc. The global BCMA-Targeted CAR-T Cell Therapy market is rapidly emerging as a transformative segment within oncology, redefining treatment paradigms for hematologic malignancies, particularly multiple myeloma. Valued for its personalized approach and precision targeting, BCMA-focused CAR-T therapies leverage a patient's immune system to combat cancer cells effectively. The growing incidence of multiple myeloma, coupled with advancements in CAR-T engineering, underscores the…
Targeting Tomorrow: Advancements and Opportunities in the BCMA-Targeted Therapy …
In today's dynamic global economy, the B cell maturation antigen targeted therapy market is emerging as a beacon of opportunity and innovation. With rapid technological advancements, evolving consumer demands, and proactive government policies shaping the landscape, this sector is setting the stage for transformative change. Our in-depth analysis delves into historical market trends, current dynamics, and future projections, providing industry leaders, investors, and decision-makers with the strategic insights needed to…
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Opportunitie …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global b-cell maturation antigen (bcma) targeted therapies market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was…
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Tri …
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights:
* Research Methodology
* Global and Regional Market Analysis
* Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
* Market and Drug Sales Insight 2020 Till 2026
* Approved Drug In Market: 2 Drugs
* Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
* Future Market Assessment By Indication Till 2026
*…
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2022 | Detailed Repor …
The B-Cell Maturation Antigen (BCMA) Targeted Therapies research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Ana …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)…
